Interview
with John Moore
John MooreJohn describes himself as an optimist but tries to be a probabilist — a reflection of his willingness to take some risk but also his fascination with what lies below the surface, off-balance sheet assets and overlooked value. This is also what drives his work across multiple industries, from biotechnology to energy. Meet John Moore, the proposed new board member for PHI (edit: see Notice of Extraordinary General Meeting in PHI AB, 2nd September 2024).
John’s extensive experience and visionary mindset make him an invaluable addition to our team. Let’s dive into his journey and what made him interested in PHI.
John, can you tell us a bit about your background and what drives your passion for innovation?
Absolutely, I’ve spent my career at the always fascinating and often frustrating intersection of technology and business, leading companies across various industries, from life sciences to energy. Currently, I serve as Chairman for Scientific Industries, Nyrada, Trialogics, and Cormetech. My work has been driven by a passion for “the big idea” and the potential for technology to transform lives for the better. I’ve led companies through significant growth phases, strategic acquisitions, and successful exits, always with an eye on innovation and market impact.
In your LinkedIn profile, you describe yourself as an optimist by nature and strive to be probability-oriented. How has this influenced your career and values?
Being an optimist allows me to see opportunities where others might see challenges, but being probability-oriented and “risk-aware” keeps me grounded. This balance has guided my decision-making process, helping me take calculated risks and learn from failures. It’s about staying humble, open-minded, and always assessing the odds to make informed, strategic decisions. This mindset has been crucial in navigating complex markets and driving growth.
Your career is marked by significant achievements. Can you share a few highlights that stand out to you?
Certainly. One of my notable experiences was leading Acorn Energy from a $10 million market cap to a $200 million valuation, driven by strategic acquisitions and public offerings. Acquiring and selling CoaLogix for $101 million was also a pivotal moment, showcasing the power of strategic investment and growth. Additionally, co-founding Edson Moore Healthcare Ventures and achieving a 300% IRR through our biotech portfolio was immensely rewarding. My background has equipped me with insights into scaling operations and navigating complex market dynamics which I think will be beneficial for PHI.
How did you first come into contact with PHI?
I learned about PHI through their collaboration with Biospherix. Our Scientific Bioprocessing business at SCND was collaborating with them both at the Wake Forest Institute for Regenerative Medicine (WFIRM) which is a terrific demonstration site for the US market.
What was it about the company that impressed you and made you accept the nomination as a board member of PHI?
PHI’s groundbreaking work in non-invasive imaging and regenerative medicine is truly impressive. However, the Altium investment and the contribution of their CEO, Goran Dubravčić, as Chairman of PHI are the difference makers. I have to be very selective about where I spend my time. My number one rule of business is “Your success has to be strategically important to somebody.” Altium has distribution and a long history of helping medical device companies succeed in the marketplace. I think I can learn a lot from the Altium and PHI team.
How do you view PHI’s current position in the market and its future potential?
Phase Holographic Imaging is well-positioned in a rapidly evolving market. Their technology has the potential to become a cornerstone in medical and research institutions worldwide. With the right strategic initiatives like WFIRM and others, I believe PHI can significantly enhance its market presence and drive revenue and profits as well as create meaningful advancements in the industry.
As a final comment, could you please tell us what you hope to achieve in your new role as a board member of PHI?
The Chairman and the CEO have a terrific plan to grow the business. I want to contribute my contacts and experience in the US market to support their plan. In the USA we have over 3,000 cell and gene therapy clinical trials underway. The FDA has a Process Analytical Technology mandate that encourages biotech companies to incorporate technologies like PHI’s HoloMonitor® into their protocols however, there is work to be done to establish the product as the quality assurance gold standard. Lastly, I am eager to help the team add AI to their product roadmap to become a total solution provider to our growing user community. I’m excited to be part of this dynamic team and contribute to Phase Holographic Imaging’s continued success.
Thank you to John for this interview!
